Pitt Street Research | Stock research
Immuron.png

Immuron

Immuron (NDQ: IMRN, ASX: IMC) is an Australian biotech company developing commercial assets that help transform the standard of care for gastrointestinal disorders. Through its proprietary technology platform, IMC creates pharmaceuticals to treat gut-mediated diseases through oral immunoglobulin-based therapies. IMC has 2 flagship commercial products – Travelan and Protectyn – and 3 clinical-stage assets – IMM-529, IMM-124E and CampETEC.

Immuron (ASX: IMC)

 

Immuron (NDQ: IMRN, ASX: IMC) is an Australian biotech company developing commercial assets that help transform the standard of care for gastrointestinal disorders. Through its proprietary technology platform, IMC creates pharmaceuticals to treat gut-mediated diseases through oral immunoglobulin-based therapies. IMC has 2 flagship commercial products – Travelan and Protectyn – and 3 clinical-stage assets – IMM-529, IMM-124E and CampETEC.